UGA Biopharma provides customised biosimilar and NBE development services. The well-established platform technology is based on different CHO host cell lines, an optimized expression vector and the proprietary First CHOice® cell culture medium.
UGA Biopharma has successfully completed a large number of biosimilar for several international biopharmaceutical companies. Our know-how and longstanding expertise in cell line development, bioprocess optimization, downstream development and analytics makes us the leading partner for your biosimilar development projects.
